Incorporating economic evaluations into decision-making: the Ontario experience.
The Drug Quality and Therapeutics Committee (DQTC) and the Canadian Expert Drug Assessment Committee (CEDAC) make reimbursement recommendations to publicly funded outpatient drug plans in Ontario and Canada respectively. In this article, the organization and decision-making processes of these committees are described. Issues associated with these committees such as potential biases associated with pharmaceutical company submissions, transparency, restricted access programs, conditional listing, and price negotiation are discussed.
Laupacis
Andreas
A
Institute for Clinical Evaluative Sciences, Division of General Internal Medicine, Sunnybrook and Women's Health Sciences Centre, and the Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. alaupacis@ices.on.ca
D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D006291:Health Policy / Q000191:economics; D006801:Humans; D009864:Ontario; D011050:Policy Making; D011785:Quality Assurance, Health Care / Q000191:economics; D012051:Reimbursement Mechanisms / Q000191:economics*